ZA200710769B - Dosage regimen for prasugrel - Google Patents

Dosage regimen for prasugrel

Info

Publication number
ZA200710769B
ZA200710769B ZA200710769A ZA200710769A ZA200710769B ZA 200710769 B ZA200710769 B ZA 200710769B ZA 200710769 A ZA200710769 A ZA 200710769A ZA 200710769 A ZA200710769 A ZA 200710769A ZA 200710769 B ZA200710769 B ZA 200710769B
Authority
ZA
South Africa
Prior art keywords
prasugrel
dosage regimen
regimen
dosage
Prior art date
Application number
ZA200710769A
Other languages
English (en)
Inventor
Brandt John Thomas
Jakubowski Joseph Anthony
Weerakkody Govinda Jayanath
Farid Nagy Alphonse
Payne Christopher David
Winters Kenneth John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA200710769B publication Critical patent/ZA200710769B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA200710769A 2005-06-17 2007-12-11 Dosage regimen for prasugrel ZA200710769B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
ZA200710769B true ZA200710769B (en) 2009-09-30

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200710769A ZA200710769B (en) 2005-06-17 2007-12-11 Dosage regimen for prasugrel

Country Status (18)

Country Link
US (1) US20090156632A1 (es)
EP (1) EP1893205A4 (es)
JP (1) JP2008543853A (es)
KR (1) KR20080016647A (es)
CN (1) CN101198329A (es)
AU (1) AU2006259538A1 (es)
BR (1) BRPI0612624A2 (es)
CA (1) CA2612315A1 (es)
EA (1) EA200800075A1 (es)
EC (1) ECSP078014A (es)
GT (1) GT200600263A (es)
IL (1) IL187486A0 (es)
MA (1) MA29722B1 (es)
MX (1) MX2007015430A (es)
NO (1) NO20080244L (es)
TN (1) TNSN07474A1 (es)
WO (1) WO2006138317A2 (es)
ZA (1) ZA200710769B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5274261B2 (ja) 2006-12-07 2013-08-28 第一三共株式会社 低置換度ヒドロキシプロピルセルロースを含有する医薬組成物
WO2008072532A1 (ja) * 2006-12-07 2008-06-19 Daiichi Sankyo Company, Limited 貯蔵安定性が改善された医薬組成物
EP2152078B8 (en) 2007-04-27 2021-03-17 CyDex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
HUE047755T2 (hu) 2009-05-13 2020-05-28 Cydex Pharmaceuticals Inc Prasugrelt és ciklodextrin-származékokat tartalmazó gyógyszerkészítmények, eljárás ezek elõállítására és alkalmazásra
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
EP3106151A1 (en) 2015-06-19 2016-12-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
HU230762B1 (hu) * 2000-07-06 2018-03-28 Daiichi Sankyo Company, Limited Hidropiridin-származékok maleát addíciós sója
ES2311498T3 (es) * 2000-12-25 2009-02-16 Daiichi Sankyo Company, Limited Composiciones medicinales que contienen aspirina.
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
EP1660183A2 (en) * 2003-05-05 2006-05-31 Eli Lilly and Company Treating cardiovascular diseases with a compound of formula 1 (cs 747 - prasugrel; rn 150322-43-4)

Also Published As

Publication number Publication date
TNSN07474A1 (en) 2009-03-17
WO2006138317A2 (en) 2006-12-28
US20090156632A1 (en) 2009-06-18
WO2006138317A3 (en) 2007-05-03
BRPI0612624A2 (pt) 2016-11-29
CA2612315A1 (en) 2006-12-28
CN101198329A (zh) 2008-06-11
NO20080244L (no) 2008-01-14
MA29722B1 (fr) 2008-09-01
EA200800075A1 (ru) 2008-04-28
AU2006259538A1 (en) 2006-12-28
KR20080016647A (ko) 2008-02-21
GT200600263A (es) 2007-02-23
MX2007015430A (es) 2008-02-21
ECSP078014A (es) 2008-01-23
EP1893205A2 (en) 2008-03-05
IL187486A0 (en) 2008-06-05
EP1893205A4 (en) 2010-06-30
JP2008543853A (ja) 2008-12-04

Similar Documents

Publication Publication Date Title
IL251539A0 (en) Single pharmaceutical dosage form
PL2343071T3 (pl) Farmaceutyczne postacie dawkowania
ZA200710769B (en) Dosage regimen for prasugrel
GB0513984D0 (en) Dosage form
PL1912626T3 (pl) Postaci użytkowe o polepszonej biodostępności
EP1778252A4 (en) NON-CARDIOTOXIC PHARMACEUTICAL COMPOUNDS
GB0427455D0 (en) Dosage forms
GB0423964D0 (en) Dosage form
ZA200803152B (en) Oramucosal pharmaceutical dosage form
GB0616794D0 (en) Solid dosage form
GB0512453D0 (en) Dosage unit
ZA200605666B (en) Solid dosage form
GB0424742D0 (en) Pharmaceutical compounds
GB0522989D0 (en) Dosage form
GB0424994D0 (en) Dosage form
GB0411047D0 (en) Dosage form
GB0411667D0 (en) Controlled-release dosage form
GB0411669D0 (en) Controlled-release dosage form
GB0425810D0 (en) Movable dosage indicator
AU304365S (en) Barrier bench
GB0423684D0 (en) Pharmaceutical compounds
GB0408239D0 (en) Pharmaceutical compounds
GB0412894D0 (en) Pharmaceutical compounds
GB0415082D0 (en) Pharmaceutical compounds
GB0415084D0 (en) Pharmaceutical compounds